1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By Tom Gallen

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

(Shutterstock)

Alfasigma has set up a consumer healthcare business in Germany to take a slice of Europe’s largest OTC market.

The privately-held Italian pharma firm is introducing to German pharmacies its Onligol gastrointestinal brand

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By David Ridley

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By Tom Gallen

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By Tom Gallen

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

More from Marketing & Advertising

Haleon’s US Eroxon Launch Falls Short Of Expectations

 
• By Tom Gallen

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

Haleon Launches 24 Hour Voltarol Medicated Plaster In The UK

 
• By David Ridley

Voltarol One A Day Muscle Pain Relief Medicated Plaster provides up to 24 hours relief from pain and inflammation, according to manufacturer Haleon.

Over The Counter: Why OTC Firms Should Care About Rx Advertising, With AdverCheck’s James Walmsley

 
• By David Ridley

HBW Insight speaks to AdverCheck managing director James Walmsley about the rise of direct-to-consumer prescription drugs marketing in the UK, and its impact on the consumer healthcare industry.